Sialic Acids in Biological and Therapeutic Processes: Opportunities and Challenges

References

• Marth JD , GrewalPK. Mammalian glycosylation in immunity. Nat. Rev. Immunol.8 (11), 874–887 (2008).
   PubMed Web of Science ®Google Scholar
• Ohtsubo K , MarthJD. Glycosylation in cellular mechanisms of health and disease. Cell126 (5), 855–867 (2006).
   PubMed Web of Science ®Google Scholar
• Dube DH , BertozziCR. Glycans in cancer and inflammation. Potential for therapeutics and diagnostics. Nat. Rev. Drug Discov.4 (6), 477–488 (2005).
   PubMed Web of Science ®Google Scholar
• Fuster MM , EskoJD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer5, 526–542 (2005).
   PubMed Web of Science ®Google Scholar
• Galan MC , Benito-AlifonsoD, WattGM. Carbohydrate chemistry in drug discovery. Org. Biomol. Chem.9 (10), 3598–3610 (2011).
   PubMed Web of Science ®Google Scholar
• Bernardes GJL , CastagnerB, SeebergerPH. Combined approaches to the synthesis and study of glycoproteins. ACS Chem. Biol.4 (9), 703–713 (2009).
   PubMed Web of Science ®Google Scholar
• Chen X , VarkiA. Advances in the biology and chemistry of sialic acids. ACS Chem. Biol.5 (2), 163–176 (2010).
   PubMed Web of Science ®Google Scholar
• Schauer R . Achievements and challenges of sialic acid research. Glycoconj. J.17 (7–9), 485–499 (2000).
   PubMed Web of Science ®Google Scholar
• Schauer R . Sialic Acids: Chemistry, Metabolism And Function. Springer-Verlag, Wien-New York (1982).
   Google Scholar
• Varki A . Sialic acids in human health and disease. Trends Mol. Med.14 (8), 351–360 (2008).
   PubMed Web of Science ®Google Scholar
• Hudak JE , CanhamSM, BertozziCR. Glycocalyx engineering reveals a siglec-based mechanism for NK cell immunoevasion. Nat. Chem. Biol.10, 69–77 (2014).
   PubMed Web of Science ®Google Scholar
• Chokhawala HA , HuangSS, LauKet al. Combinatorial chemoenzymatic synthesis and high-throughput screening of sialosides. ACS Chem. Biol.3 (9), 567–576 (2008).
   PubMed Web of Science ®Google Scholar
• Crocker PR , VarkiA. Siglecs in the immune system. Immunology103 (2), 137–145 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens J , BlixtO, PaulsonJC, WilsonIA. Glycan microarray technologies: tools to survey host specificity of influenza viruses. Nat. Rev. Microbiol.4 (11), 857–864 (2006).
   PubMed Web of Science ®Google Scholar
• Varki A , CummingsRD, EskoJDet al. Essentials of Glycobiology . Cold Spring Harbour Press, CA, USA (2008).
   Google Scholar
• Rao FV , RichJR, RakicBet al. Structural insight into mammalian sialyltransferases. Nat. Struct. Mol. Biol.16 (11), 1186–1188 (2009).
   PubMed Web of Science ®Google Scholar
• Rillahan C , SchwartzE, RademacherCet al. On-chip synthesis and screening of a sialoside library yields a high affinity ligand for siglec-7. ACS Chem. Biol.8, 1417–1422 (2013).
   PubMed Web of Science ®Google Scholar
• Macauley MS , CrockerPR, PaulsonJC. Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol.14, 653–666 (2014).
   PubMed Web of Science ®Google Scholar
• Cazet A , JulienS, BobowskiM, BurchellJ, DelannoyP. Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res.12 (3), 204 (2010).
   PubMed Web of Science ®Google Scholar
• Cazet A , JulienS, BobowskiMet al. Consequences of the expression of sialylated antigens in breast cancer. Carbohydr. Res.345 (10), 1377–1383 (2010).
   PubMed Web of Science ®Google Scholar
• Ernst B , MagnaniJL. From carbohydrate leads to glycomimetic drugs. Nat. Rev. Drug Discov.8 (8), 661–677 (2009).
   PubMed Web of Science ®Google Scholar
• Lowe JB , MarthJD. A genetic approach to mammalian glycan function. Annu. Rev. Biochem.72, 643–691 (2003).
   PubMed Web of Science ®Google Scholar
• Filser C , KowalczykD, JonesCet al. Synthetic glycopeptides from the e-selectin ligand 1 with varied sialyl lewis(x) structure as cell-adhesion inhibitors of E-selectin. Angew. Chem. Int. Ed. Engl.46 (12), 2108–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat. Rev. Drug Discov.10 (12), 890–890 (2011).
   Web of Science ®Google Scholar
• Clinical Trials Database. www.clinicaltrials.gov.
   Google Scholar
• Watz H , BockD, MeyerMet al. Inhaled pan-selectin antagonist bimosiamose attenuates airway inflammation in COPD. Pulm. Pharmacol. Ther.26 (2), 265–270 (2013).
   PubMed Web of Science ®Google Scholar
• Mesch S , MoserD, StrasserDSet al. Low molecular weight antagonists of the myelin-associated glycoprotein: synthesis, docking, and biological evaluation. J. Med. Chem.53 (4), 1597–1615 (2010).
   PubMed Web of Science ®Google Scholar
• Magano J . Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza. Chem. Rev.109 (9), 4398–4438 (2009).
   PubMed Web of Science ®Google Scholar
• Pera NP , BranderhorstHM, KooijRet al. Rapid screening of lectins for multivalency effects with a glycodendrimer microarray. Chembiochem11 (13), 1896–1904 (2010).
   PubMed Web of Science ®Google Scholar
• Chen WC , SigalDS, SavenA, PaulsonJC. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Leuk. Lymphoma53 (2), 208–210 (2012).
   PubMed Web of Science ®Google Scholar
• Chen WC , KawasakiN, NycholatCMet al. Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169. PloS ONE7 (6), e39039 (2012).
   PubMed Web of Science ®Google Scholar
• Blixt O , HanSF, LiaoLet al. Sialoside analogue arrays for rapid identification of high affinity siglec ligands. J. Am. Chem. Soc.2130 (21), 6680–6681 (2008).
   Google Scholar
• Rillahan CD , MacauleyMS, SchwartzEet al. Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas. Chem. Sci.5, 2398–2406 (2014).
   PubMed Web of Science ®Google Scholar
• Jandus C , SimonH-U, Von GuntenS. Targeting siglecs-A novel pharmacological strategy for immuno- and glycotherapy. Biochem. Pharmacol.82 (4), 323–332 (2011).
   PubMed Web of Science ®Google Scholar
• O'Reilly MK , PaulsonJC. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol. Sci.30 (5), 240–248 (2009).
   PubMed Web of Science ®Google Scholar
• US FDA . www.fda.gov.
   Google Scholar
• Zhu J , WanQ, RagupathiG, GeorgeCM, LivingstonPO, DanishefskySJ. Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer orchestration of oligosaccharide and polypeptide domains. J. Am. Chem. Soc.131 (11), 4151–4158 (2009).
   PubMed Web of Science ®Google Scholar
• Zhu J , WarrenJD, DanishefskySJ. Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience. Expert Rev. Vaccines8 (10), 1399–1413 (2009).
   PubMed Web of Science ®Google Scholar
• Astronomo RD , BurtonDR. Carbohydrate vaccines: developing sweet solutions to sticky situations?Nat. Rev. Drug Disov.9 (4), 308–324 (2010).
   PubMed Web of Science ®Google Scholar
• Zeichner SB . The failed theratope vaccine: 10 years later. J. Am. Osteopath. Assoc.112 (8), 482–483 (2012).
   PubMedGoogle Scholar
• Wilson RM , DanishefskySJ. A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic. J. Am. Chem. Soc.135, 14462–14472 (2013).
   PubMed Web of Science ®Google Scholar
• Danishefsky SJ , ShueY-K, ChangC-H. Development of Globo-H cancer vaccine. Acc. Chem. Res.48, 643–652 (2015).
   PubMed Web of Science ®Google Scholar
• Byrne B , DonohoeGG, O'KennedyR. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Discov. Today12 (7–8), 319–326 (2007).
   PubMed Web of Science ®Google Scholar